Vincent Molinié
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Vincent Molinié has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
A Vieillefond
6 shared publicationsAndré Balaton
6 shared publicationsB Cochand-Priollet
5 shared publicationsGaëlle Fromont
3 shared publicationsM C Dauge-Geffroy
3 shared publicationsMarc De Fromont
3 shared publications
Latest Publications
- 30 June 2012
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 29 (6) , 836-843
L’examen extemporané en pathologie thoracique. Le point de vue du pathologiste
- 30 June 2012
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 29 (6) , 836-843
L’examen extemporané en pathologie thoracique. Le point de vue du pathologiste
- 1 April 2012
- Published by Elsevier in Annales de Pathologie
- Vol. 32 (2) , 114-117
Difficultés d’interprétation des biopsies prostatiques. Cas no 2. Hyperplasie adénomateuse atypique (adénose)
- 1 April 2012
- Published by Elsevier in Annales de Pathologie
- Vol. 32 (2) , 114-117
Difficultés d’interprétation des biopsies prostatiques. Cas no 2. Hyperplasie adénomateuse atypique (adénose)
- 1 April 2012
- Published by Elsevier in Annales de Pathologie
- Vol. 32 (2) , 107-113
Difficultés d’interprétation des biopsies prostatiques. Cas no 1. Microfoyer d’adénocarcinome acinaire
- 1 April 2012
- Published by Elsevier in Annales de Pathologie
- Vol. 32 (2) , 107-113
Difficultés d’interprétation des biopsies prostatiques. Cas no 1. Microfoyer d’adénocarcinome acinaire
- 1 March 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (7) , 408
Parafibromin as a new immunohistochemistry staining to improve pathologic diagnosis of renal oncocytoma: Analysis of 225 renal tumors.
408 Background: Chromophobe renal cell carcinoma (chRCC) and renal oncocytoma (Onc) are two distinct but closely related entities with strong morphologic and genetic similarities. While chRCC is a malignant tumor, Onc is usually considered as a benign entity. Recently, gene expression profiling applied on chRCC and Onc identified new potential markers that may effectively discriminate the 2 pathologic entities, including parafibromin. This work aims at evaluating the diagnostic value of Parafibromin (Pf) immuno staining on a large number of renal tumor samples. Methods: Sixty-three renal clear cell carcinoma (ccRCC), 47 papillary (Pap), 40 chRCC, and 75 Onc were immunostained for parafibromin antibody (1/200; Santacruz Biotechnology), on a tissue micro array. Results: Parafibromin was positive in 38.6% of Onc, vs 5% of chRCC (p < 0.001), with a 95% specificity, and the positive predictive value observed for parafibromin was 94%. For other tumor types, a positive staining for parafibromin was observed in 7.9% and 8.5% in ccRCC and Pap respectively. Conclusions: Parafibromin is a recently identified protein which seems to be specific for oncocytoma, and highly discriminant for other histologic renal cell tumor subtypes, especially for chromophobe. IHC may help to optimize therapeutics strategy for small renal mass and avoid surgical resection of benign lesions in some patients.Validation of this staining on renal tumor biopsies is on going.The value of the combination of this new immunostaining associated with the three standard IHC staining (CK7, CD117, E Cad) will be provided at the meeting. [Table: see text] No significant financial relationships to disclose.
- 1 March 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (7) , 408
Parafibromin as a new immunohistochemistry staining to improve pathologic diagnosis of renal oncocytoma: Analysis of 225 renal tumors.
408 Background: Chromophobe renal cell carcinoma (chRCC) and renal oncocytoma (Onc) are two distinct but closely related entities with strong morphologic and genetic similarities. While chRCC is a malignant tumor, Onc is usually considered as a benign entity. Recently, gene expression profiling applied on chRCC and Onc identified new potential markers that may effectively discriminate the 2 pathologic entities, including parafibromin. This work aims at evaluating the diagnostic value of Parafibromin (Pf) immuno staining on a large number of renal tumor samples. Methods: Sixty-three renal clear cell carcinoma (ccRCC), 47 papillary (Pap), 40 chRCC, and 75 Onc were immunostained for parafibromin antibody (1/200; Santacruz Biotechnology), on a tissue micro array. Results: Parafibromin was positive in 38.6% of Onc, vs 5% of chRCC (p < 0.001), with a 95% specificity, and the positive predictive value observed for parafibromin was 94%. For other tumor types, a positive staining for parafibromin was observed in 7.9% and 8.5% in ccRCC and Pap respectively. Conclusions: Parafibromin is a recently identified protein which seems to be specific for oncocytoma, and highly discriminant for other histologic renal cell tumor subtypes, especially for chromophobe. IHC may help to optimize therapeutics strategy for small renal mass and avoid surgical resection of benign lesions in some patients.Validation of this staining on renal tumor biopsies is on going.The value of the combination of this new immunostaining associated with the three standard IHC staining (CK7, CD117, E Cad) will be provided at the meeting. [Table: see text] No significant financial relationships to disclose.
- Open Access
- 12 May 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 196
Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma
Chromophobe renal cell carcinoma (chRCC) and renal oncocytoma are two distinct but closely related entities with strong morphologic and genetic similarities. While chRCC is a malignant tumor, oncocytoma is usually regarded as a benign entity. The overlapping characteristics are best explained by a common cellular origin, and the biologic differences between chRCC and oncocytoma are therefore of considerable interest in terms of carcinogenesis, diagnosis and clinical management. Previous studies have been relatively limited in terms of examining the differences between oncocytoma and chromophobe RCC. Gene expression profiling using the Affymetrix HGU133Plus2 platform was applied on chRCC (n = 15) and oncocytoma specimens (n = 15). Supervised analysis was applied to identify a discriminatory gene signature, as well as differentially expressed genes. High throughput single-nucleotide polymorphism (SNP) genotyping was performed on independent samples (n = 14) using Affymetrix GeneChip Mapping 100 K arrays to assess correlation between expression and gene copy number. Immunohistochemical validation was performed in an independent set of tumors. A novel 14 probe-set signature was developed to classify the tumors internally with 93% accuracy, and this was successfully validated on an external data-set with 94% accuracy. Pathway analysis highlighted clinically relevant dysregulated pathways of c-erbB2 and mammalian target of rapamycin (mTOR) signaling in chRCC, but no significant differences in p-AKT or extracellular HER2 expression was identified on immunohistochemistry. Loss of chromosome 1p, reflected in both cytogenetic and expression analysis, is common to both entities, implying this may be an early event in histogenesis. Multiple regional areas of cytogenetic alterations and corresponding expression biases differentiating the two entities were identified. Parafibromin, aquaporin 6, and synaptogyrin 3 were novel immunohistochemical markers effectively discriminating the two pathologic entities. Gene expression profiles, high-throughput SNP genotyping, and pathway analysis effectively distinguish chRCC from oncocytoma. We have generated a novel transcript predictor that is able to discriminate between the two entities accurately, and which has been validated both in an internal and an independent data-set, implying generalizability. A cytogenetic alteration, loss of chromosome 1p, common to renal oncocytoma and chRCC has been identified, providing the opportunities for identifying novel tumor suppressor genes and we have identified a series of immunohistochemical markers that are clinically useful in discriminating chRCC and oncocytoma.
- 12 May 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 196
Open AccessGenomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma
Chromophobe renal cell carcinoma (chRCC) and renal oncocytoma are two distinct but closely related entities with strong morphologic and genetic similarities. While chRCC is a malignant tumor, oncocytoma is usually regarded as a benign entity. The overlapping characteristics are best explained by a common cellular origin, and the biologic differences between chRCC and oncocytoma are therefore of considerable interest in terms of carcinogenesis, diagnosis and clinical management. Previous studies have been relatively limited in terms of examining the differences between oncocytoma and chromophobe RCC. Gene expression profiling using the Affymetrix HGU133Plus2 platform was applied on chRCC (n = 15) and oncocytoma specimens (n = 15). Supervised analysis was applied to identify a discriminatory gene signature, as well as differentially expressed genes. High throughput single-nucleotide polymorphism (SNP) genotyping was performed on independent samples (n = 14) using Affymetrix GeneChip Mapping 100 K arrays to assess correlation between expression and gene copy number. Immunohistochemical validation was performed in an independent set of tumors. A novel 14 probe-set signature was developed to classify the tumors internally with 93% accuracy, and this was successfully validated on an external data-set with 94% accuracy. Pathway analysis highlighted clinically relevant dysregulated pathways of c-erbB2 and mammalian target of rapamycin (mTOR) signaling in chRCC, but no significant differences in p-AKT or extracellular HER2 expression was identified on immunohistochemistry. Loss of chromosome 1p, reflected in both cytogenetic and expression analysis, is common to both entities, implying this may be an early event in histogenesis. Multiple regional areas of cytogenetic alterations and corresponding expression biases differentiating the two entities were identified. Parafibromin, aquaporin 6, and synaptogyrin 3 were novel immunohistochemical markers effectively discriminating the two pathologic entities. Gene expression profiles, high-throughput SNP genotyping, and pathway analysis effectively distinguish chRCC from oncocytoma. We have generated a novel transcript predictor that is able to discriminate between the two entities accurately, and which has been validated both in an internal and an independent data-set, implying generalizability. A cytogenetic alteration, loss of chromosome 1p, common to renal oncocytoma and chRCC has been identified, providing the opportunities for identifying novel tumor suppressor genes and we have identified a series of immunohistochemical markers that are clinically useful in discriminating chRCC and oncocytoma.
- 1 October 2008
- Published by Elsevier in Annales de Pathologie
- Vol. 28 (5) , 467-473
Fiche compte rendu standardisé et prostatectomie radicale
- 1 October 2008
- Published by Elsevier in Annales de Pathologie
- Vol. 28 (5) , 467-473
Fiche compte rendu standardisé et prostatectomie radicale
- 1 October 2008
- Published by Elsevier in Annales de Pathologie
- Vol. 28 (5) , 354-362
Biologie moléculaire et cancer de prostate : évolution ou révolution ?
- 1 October 2008
- Published by Elsevier in Annales de Pathologie
- Vol. 28 (5) , 354-362
Biologie moléculaire et cancer de prostate : évolution ou révolution ?
- 1 October 2008
- Published by Elsevier in Annales de Pathologie
- Vol. 28 (5) , 417-423
Évaluation des marqueurs p63 et p504s dans le diagnostic du cancer de prostate
- 1 October 2008
- Published by Elsevier in Annales de Pathologie
- Vol. 28 (5) , 417-423
Évaluation des marqueurs p63 et p504s dans le diagnostic du cancer de prostate
- 1 October 2008
- Published by Elsevier in Annales de Pathologie
- Vol. 28 (5) , 424-428
Biopsies prostatiques : combien de prélèvements et combien de flacons ? Défi économique et efficacité
- 1 October 2008
- Published by Elsevier in Annales de Pathologie
- Vol. 28 (5) , 424-428
Biopsies prostatiques : combien de prélèvements et combien de flacons ? Défi économique et efficacité
- 1 October 2008
- Published by Elsevier in Annales de Pathologie
- Vol. 28 (5) , 429-458
Le compte rendu standardisé en pathologie cancérologique urologique
- 1 October 2008
- Published by Elsevier in Annales de Pathologie
- Vol. 28 (5) , 429-458
Le compte rendu standardisé en pathologie cancérologique urologique